Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

Pasoon Hellamand; Marleen G H Van de Sande; Lykke Midtbøll Ørnbjerg; Thomas Klausch; N Trokovic; Tuulikki Sokka-Isler; R Van Vollenhoven; D.C. Nordström; MJ Santos; Elsa Vieira-Sousa; A. G. Loft; Bente Glintborg; Mikkel Østergaard; U Lindström; Johan Karlsson Wallman; Brigitte Michelsen; B. Moeller; Raphael  Micheroli; Catalin Codreanu; C Moogosan; Karin Laas; Z Roter; Karen Minde Fagerli; M Tomsic; I Castrejon; M Pombo-Suarez; B Gudbjörnsson; T Love; K. Pavelka; Jakub Závada; G Kenar; H Yarkan-Tugsai; Merete Lund Hetland; I Van der Horst- Bruinsma

Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

Pasoon Hellamand, Marleen G H Van de Sande, Lykke Midtbøll Ørnbjerg, Thomas Klausch, N Trokovic, Tuulikki Sokka-Isler, R Van Vollenhoven, D.C. Nordström, MJ Santos, Elsa Vieira-Sousa, A. G. Loft, Bente Glintborg, Mikkel Østergaard, U Lindström, Johan Karlsson Wallman, Brigitte Michelsen, B. Moeller, Raphael Micheroli, Catalin Codreanu, C MoogosanKarin Laas, Z Roter, Karen Minde Fagerli, M Tomsic, I Castrejon, M Pombo-Suarez, B Gudbjörnsson, T Love, K. Pavelka, Jakub Závada, G Kenar, H Yarkan-Tugsai, Merete Lund Hetland, I Van der Horst- Bruinsma

Department for Rheumatology and Spine Diseases

Abstract

Background:
Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

Original language	English
Publication date	2022
Publication status	Published - 2022
Event	EULAR 2022 - Copenhagen Duration: 1 Jun 2022 → 4 Jun 2022

Conference

Conference	EULAR 2022
City	Copenhagen
Period	01/06/2022 → 04/06/2022

Cite this

Hellamand, P., Van de Sande, M. G. H., Ørnbjerg, L. M., Klausch, T., Trokovic, N., Sokka-Isler, T., Van Vollenhoven, R., Nordström, D. C., Santos, MJ., Vieira-Sousa, E., Loft, A. G., Glintborg, B., Østergaard, M., Lindström, U., Wallman, J. K., Michelsen, B., Moeller, B., Micheroli, R., Codreanu, C., ... Van der Horst- Bruinsma, I. (2022). Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network. Annals of the Rheumatic Diseases 81 Suppl 1: 257. Abstract from EULAR 2022, Copenhagen.

Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network. / Hellamand, Pasoon; Van de Sande, Marleen G H; Ørnbjerg, Lykke Midtbøll et al.
2022. Annals of the Rheumatic Diseases 81 Suppl 1: 257 Abstract from EULAR 2022, Copenhagen.

Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

Hellamand, P, Van de Sande, MGH, Ørnbjerg, LM, Klausch, T, Trokovic, N, Sokka-Isler, T, Van Vollenhoven, R, Nordström, DC, Santos, MJ, Vieira-Sousa, E, Loft, AG, Glintborg, B , Østergaard, M, Lindström, U, Wallman, JK, Michelsen, B, Moeller, B, Micheroli, R, Codreanu, C, Moogosan, C, Laas, K, Roter, Z, Fagerli, KM, Tomsic, M, Castrejon, I, Pombo-Suarez, M, Gudbjörnsson, B, Love, T, Pavelka, K, Závada, J, Kenar, G, Yarkan-Tugsai, H, Hetland, ML & Van der Horst- Bruinsma, I 2022, 'Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network', EULAR 2022, Copenhagen, 01/06/2022 - 04/06/2022 pp. Annals of the Rheumatic Diseases 81 Suppl 1: 257.

@conference{5f9cd59ce036437b83daeaa608026bd0,

title = "Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network",

abstract = "Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.",

author = "Pasoon Hellamand and {Van de Sande}, {Marleen G H} and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Thomas Klausch and N Trokovic and Tuulikki Sokka-Isler and {Van Vollenhoven}, R and D.C. Nordstr{\"o}m and MJ Santos and Elsa Vieira-Sousa and Loft, {A. G.} and Bente Glintborg and Mikkel {\O}stergaard and U Lindstr{\"o}m and Wallman, {Johan Karlsson} and Brigitte Michelsen and B. Moeller and Raphael Micheroli and Catalin Codreanu and C Moogosan and Karin Laas and Z Roter and Fagerli, {Karen Minde} and M Tomsic and I Castrejon and M Pombo-Suarez and B Gudbj{\"o}rnsson and T Love and K. Pavelka and Jakub Z{\'a}vada and G Kenar and H Yarkan-Tugsai and Hetland, {Merete Lund} and {Van der Horst- Bruinsma}, I",

note = "COPECARE; EULAR 2022 ; Conference date: 01-06-2022 Through 04-06-2022",

year = "2022",

language = "English",

pages = "Annals of the Rheumatic Diseases 81 Suppl 1: 257",

}

TY - ABST

T1 - Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

AU - Hellamand, Pasoon

AU - Van de Sande, Marleen G H

AU - Ørnbjerg, Lykke Midtbøll

AU - Klausch, Thomas

AU - Trokovic, N

AU - Sokka-Isler, Tuulikki

AU - Van Vollenhoven, R

AU - Nordström, D.C.

AU - Santos, MJ

AU - Vieira-Sousa, Elsa

AU - Loft, A. G.

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Lindström, U

AU - Wallman, Johan Karlsson

AU - Michelsen, Brigitte

AU - Moeller, B.

AU - Micheroli, Raphael

AU - Codreanu, Catalin

AU - Moogosan, C

AU - Laas, Karin

AU - Roter, Z

AU - Fagerli, Karen Minde

AU - Tomsic, M

AU - Castrejon, I

AU - Pombo-Suarez, M

AU - Gudbjörnsson, B

AU - Love, T

AU - Pavelka, K.

AU - Závada, Jakub

AU - Kenar, G

AU - Yarkan-Tugsai, H

AU - Hetland, Merete Lund

AU - Van der Horst- Bruinsma, I

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

AB - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

M3 - Conference abstract for conference

SP - Annals of the Rheumatic Diseases 81 Suppl 1: 257

T2 - EULAR 2022

Y2 - 1 June 2022 through 4 June 2022

ER -

Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

Abstract

Conference

Fingerprint

Cite this